Skip to main content
. 2024 Jan 7;15(6):439–447. doi: 10.1111/1759-7714.15211

FIGURE 4.

FIGURE 4

A nomogram was used to predict IDFS in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab. AI, aromatase inhibitor; IDFS, invasive disease‐free survival; OFS, ovarian function suppression; PR, progesterone receptor; TAM, tamoxifen; TOR, toremifene.